tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INCY Stock Latest News

Incyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors
Company AnnouncementsIncyte’s Phase 3 Povorcitinib Study in Hidradenitis Suppurativa Reaches Completion, Setting Up Key Catalyst for INCY Investors
3d ago
INCY
Incyte price target raised to $90 from $80 at Goldman Sachs
PremiumThe Fly
Incyte price target raised to $90 from $80 at Goldman Sachs
4d ago
INCY
Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
PremiumCompany Announcements
Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
5d ago
INCY
3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026
PremiumMarket News
3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026
5d ago
FBT
AAPL
Palvella Therapeutics appoints Vimal Patel as SVP, medical affairs
PremiumThe Fly
Palvella Therapeutics appoints Vimal Patel as SVP, medical affairs
5d ago
INCY
PVLA
Balanced Risk-Reward for Incyte as Monjuvi’s Frontline DLBCL Win Offers Modest Upside in a Crowded Market
PremiumRatingsBalanced Risk-Reward for Incyte as Monjuvi’s Frontline DLBCL Win Offers Modest Upside in a Crowded Market
7d ago
INCY
Morning Movers: Incyte gains following frontMIND trial results
Premium
The Fly
Morning Movers: Incyte gains following frontMIND trial results
7d ago
BKR
CVX
Incyte announces frontMIND trial meets primary, secondary endpoints
Premium
The Fly
Incyte announces frontMIND trial meets primary, secondary endpoints
7d ago
INCY
Incyte price target raised to $103 from $93 at Truist
PremiumThe Fly
Incyte price target raised to $103 from $93 at Truist
19d ago
INCY
Incyte announces approval of Zynyz combination in Japan
PremiumThe Fly
Incyte announces approval of Zynyz combination in Japan
21d ago
INCY
Incyte Steps Into Late-Stage Colorectal Cancer Race With New Phase 3 Trial of INCA33890
PremiumCompany Announcements
Incyte Steps Into Late-Stage Colorectal Cancer Race With New Phase 3 Trial of INCA33890
25d ago
INCY
Incyte announces European Commission approval of second indication for Minjuvi
PremiumThe Fly
Incyte announces European Commission approval of second indication for Minjuvi
26d ago
INCY
Incyte’s mCALR Monoclonal Antibody Shows Promise Amid Complex Myelofibrosis and Thrombocythemia Treatment Landscape
PremiumRatingsIncyte’s mCALR Monoclonal Antibody Shows Promise Amid Complex Myelofibrosis and Thrombocythemia Treatment Landscape
28d ago
INCY
Incyte’s Latest Study Completion: A Step Forward in Drug Interaction Insights
Premium
Company Announcements
Incyte’s Latest Study Completion: A Step Forward in Drug Interaction Insights
29d ago
INCY
Incyte Board Member Hervé Hoppenot Retires
Premium
Company Announcements
Incyte Board Member Hervé Hoppenot Retires
1M ago
8K
INCY
Incyte’s Financial Outlook Dims Amidst Challenges with Opzelura and Jakafi
PremiumRatings
Incyte’s Financial Outlook Dims Amidst Challenges with Opzelura and Jakafi
1M ago
INCY
Incyte presents updated positive data at ASH
PremiumThe Fly
Incyte presents updated positive data at ASH
1M ago
INCY
Incyte price target raised to $118 from $114 at BofA
PremiumThe Fly
Incyte price target raised to $118 from $114 at BofA
1M ago
INCY
Incyte price target raised to $92 from $86 at Morgan Stanley
PremiumThe Fly
Incyte price target raised to $92 from $86 at Morgan Stanley
1M ago
INCY
Galecto price target raised to $36 from $32 at Guggenheim
PremiumThe FlyGalecto price target raised to $36 from $32 at Guggenheim
1M ago
GLTO
INCY
Incyte’s Mutant CALR Antibody Shows Promise but Faces Uncertainties: Hold Rating Issued
Premium
Ratings
Incyte’s Mutant CALR Antibody Shows Promise but Faces Uncertainties: Hold Rating Issued
1M ago
INCY
Incyte’s INCA033989: Promising Myelofibrosis Treatment Drives Buy Rating
Premium
Ratings
Incyte’s INCA033989: Promising Myelofibrosis Treatment Drives Buy Rating
1M ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >